Henry Rodriguez

Director, OCCPR, NCI, NIH | This is my personal a/c | tweets=my own. LinkedIn:

[Henry Rodriguez @RodriguezPhDMBA]

It is a true honor to be featured in @CancerWorldmag. Let us continue to push the boundaries of healthcare in order to give patients hope.

[CancerWorld @CancerWorldmag]

Hugely encouraging to hear from @theNCI's @RodriguezPhDMBA about the value he places on working across borders and breaking down silos in his efforts to drive next steps in cancer precision medicine https://t.co/K2xoWLkXun #proteogenomics #CancerMoonshot #HorizonEU

[Henry Rodriguez @RodriguezPhDMBA]

Headed to #AACR25 in Chicago? Don’t miss the cutting-edge science from @theNCI #CPTAC—check out our posters & presentations throughout the event. Let’s connect next week! 🔬

[Henry Rodriguez @RodriguezPhDMBA]

Cancer Reimagined: The @theNCI #CPTAC scientists just mapped 130+ tumor sections across 6 cancers -using spatial & single-cell next-gen analysis. Spatial context is rewriting the cancer playbook. https://t.co/OyydVsSq9w

[Henry Rodriguez @RodriguezPhDMBA]

Accelerate your cancer research with the @theNCI Antibody Characterization Program. Submit target requests now to access affordable, validated reagents: For more info, click here https://t.co/wH6PzboAh9

[Henry Rodriguez @RodriguezPhDMBA]

Big news in QUANTITATIVE proteomics! Researchers from @UMich & @MonashUni have launched FragPipe-Analyst: a user-friendly, web-based tool to complement the popular FragPipe platform. Upload files, analyze, & visualize data with ease. #Precisionmedicine
https://t.co/iSNCf7NK5B

[Henry Rodriguez @RodriguezPhDMBA]

Promising results from a phase II trial on high-risk melanoma! Vidutolimod + nivolumab as neoadjuvant treatment shows potential, thanks to @UPMCHillmanCC, @theNCI, & @NIH_CPTAC's assays and proteogenomics insights. Clinical trials driving innovation! https://t.co/9BcZdBx0Bp

[Henry Rodriguez @RodriguezPhDMBA]

That's a wrap—for now! Our Town Hall session was a great success, sparking insightful discussions and thoughtful questions on driving the next quantum leap in precision medicine (NextGen multi-omics, AI-driven diagnostic tests to patient care). Scan the QR code to get involved!

[Henry Rodriguez @RodriguezPhDMBA]

Ab Seekers: The @theNCI Antibody Characterization Program is now accepting target requests for biomarker and cancer diagnostics research, open from Nov 1, 2024, to Feb 14, 2025. Researchers can apply to accelerate Dx and Rx advancements: https://t.co/F3myDFeMNL

[Henry Rodriguez @RodriguezPhDMBA]

The @theNCI Proteomic Data Commons (PDC) was recently featured in the @AACR's journal, @CRC_AACR. Discover how the PDC is empowering researchers to make comprehensive data-driven discoveries in our latest Resource Spotlight. https://t.co/sUQHHl2oLz

[Henry Rodriguez @RodriguezPhDMBA]

Excited to co-chair a Town Hall in Philly on Nov 1-2! Join us for an inspiring discussion with leaders in #precisionmedicine. Our goal: create a tipping point for the next leap in predictive biomarkers by tackling barriers and finding actionable solutions. https://t.co/eYyFG3RIPY

[Henry Rodriguez @RodriguezPhDMBA]

Uniting cancer research labs worldwide in the fight against cancer! @theNCI International Cancer Proteogenome Consortium (ICPC) just wrapped its annual meeting in Dresden, Germany. Progress made, still more to tackle… as cancer has no borders. #CancerResearch #HUPO2024

[Henry Rodriguez @RodriguezPhDMBA]

Excited to speak at the #2024CBTNSummit! I'll be sharing @theNCI Clinical Proteomic Tumor Analysis Consortium (#CPTAC) projects with the @wearecbtn (Children's Brain Tumor Network) and how to access proteomics data through the NCI Proteomic Data Commons (https://t.co/X5DjIGPF6e).

[Henry Rodriguez @RodriguezPhDMBA]

Researchers are making strides in single-cell proteomics (SCP), crucial for understanding cancer at the cellular level. A new workflow by @theNCI #CPTAC scientists @broadinstitute aims to boost accuracy and reproducibility in SCP. https://t.co/WBYIqASwaO

[Henry Rodriguez @RodriguezPhDMBA]

Exciting progress in #PancreaticCancer research! Scientists create a pipeline using machine learning and patient data to find new prognostic factors from
@theNCI #CPTAC multi-omics datasets. #AI Check it out: https://t.co/O29vUNPsGp

[Henry Rodriguez @RodriguezPhDMBA]

The @theNCI's Proteomic Data Commons now supports mass spec-based metabolomics & lipidomics data, including raw files, harmonized metadata, and processed data. 🚀 https://t.co/2VJMlsoP6z

[Henry Rodriguez @RodriguezPhDMBA]

Exciting progress in cancer research! 🎉 A new @theNCI #CPTAC international collaboration study has identified hundreds of potential drug targets, opening the door to innovative treatments. 📷#CancerResearch
https://t.co/LRJaRs1btx

[Henry Rodriguez @RodriguezPhDMBA]

Exciting news from CPTAC! Researchers developed a IO-3 assay panel, an immuno-oncology Dx tool. It's a comprehensive & precise way to analyze immune responses, enhancing the existing IO-1 and IO-2 panels. Now available to the public! #ImmunoOncology https://t.co/WSe6aRbC6o

[Henry Rodriguez @RodriguezPhDMBA]

Join us for the @theNCI #CPTAC Early Career Investigator Series! 🌟 Dive into bioinformatics, proteogenomics, and research ethics with Dr. Fernanda Martins Rodrigues, a post-doc at Washington University School of Medicine, St. Louis. Don't miss out! https://t.co/ULuPGVufMF

[Henry Rodriguez @RodriguezPhDMBA]

Access now:
• Visit @theNCI #CPTAC Assay Portal https://t.co/XQkAv6HWPm
• Select Available Assays
• Search ‘McGill’, ‘Fred Hutch’, or ‘Cell Signaling’

[Henry Rodriguez @RodriguezPhDMBA]

Excited to announce 3 new sets of targeted proteomic assays on @theNCI CPTAC Assay Portal!
1. McGill: 48 proteins linked to breast cancer and capivasertib response.
2. Hutch: 43 peptides for cancer immune response.
3. Cell Signaling: 10 phosphopeptides for key signaling proteins.

[Henry Rodriguez @RodriguezPhDMBA]

The @theNCI #CPTAC researchers just conducted a multi-omic analysis of high-grade glioma tumors. Novel regulatory mechanisms and potential therapy targets were uncovered, creating a valuable community data resource for the cancer research community. https://t.co/cQP3dUfC6t